ID: ALA2298865

Max Phase: Preclinical

Molecular Formula: C24H19ClN4O4S

Molecular Weight: 494.96

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NCC(=O)N1c2ccccc2Sc2ccccc21)NN1C(=O)C(Cl)C1c1ccc(O)cc1

Standard InChI:  InChI=1S/C24H19ClN4O4S/c25-21-22(14-9-11-15(30)12-10-14)29(23(21)32)27-24(33)26-13-20(31)28-16-5-1-3-7-18(16)34-19-8-4-2-6-17(19)28/h1-12,21-22,30H,13H2,(H2,26,27,33)

Standard InChI Key:  BFPGYRHRSQTPCL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 494.96

Molecular Weight (Monoisotopic): 494.0816

AlogP: 3.93

#Rotatable Bonds: 4

Polar Surface Area: 101.98

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.16

CX Basic pKa:

CX LogP: 3.20

CX LogD: 3.20

Aromatic Rings: 3

Heavy Atoms: 34

QED Weighted: 0.38

Np Likeness Score: -0.54

References

1. Rajasekaran A, Devi KS.  (2013)  Synthesis and biological evaluation of 1-(3-chloro-2-oxo-4-phenylazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)urea derivatives,  22  (6): [10.1007/s00044-012-0255-z]

Source

Source(1):

• Scientific Literature